StockNews.com Downgrades Seres Therapeutics (NASDAQ:MCRB) to Sell

StockNews.com cut shares of Seres Therapeutics (NASDAQ:MCRB) from a hold rating to a sell rating in a report issued on Monday.

Other research analysts have also issued research reports about the stock. Chardan Capital decreased their target price on shares of Seres Therapeutics from $8.00 to $6.00 and set a buy rating on the stock in a research report on Wednesday, May 8th. Oppenheimer reiterated a market perform rating on shares of Seres Therapeutics in a research report on Friday, June 7th. Finally, Canaccord Genuity Group dropped their price objective on shares of Seres Therapeutics from $15.00 to $10.00 and set a buy rating for the company in a research note on Friday, June 7th.

Seres Therapeutics Price Performance

Shares of NASDAQ:MCRB opened at $0.72 on Monday. The company’s 50 day moving average price is $0.88 and its two-hundred day moving average price is $0.98. Seres Therapeutics has a 12-month low of $0.54 and a 12-month high of $5.29. The firm has a market cap of $109.35 million, a PE ratio of -1.20 and a beta of 1.98.

Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.09. On average, research analysts expect that Seres Therapeutics will post -1.03 EPS for the current year.

Institutional Investors Weigh In On Seres Therapeutics

Several large investors have recently modified their holdings of MCRB. Mirae Asset Global Investments Co. Ltd. bought a new stake in Seres Therapeutics in the first quarter valued at $39,000. Tower Research Capital LLC TRC increased its stake in Seres Therapeutics by 668.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 38,091 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 33,135 shares in the last quarter. SG Americas Securities LLC bought a new stake in Seres Therapeutics in the fourth quarter valued at $73,000. Virtu Financial LLC bought a new stake in shares of Seres Therapeutics during the first quarter worth about $73,000. Finally, Pennant Investors LP bought a new stake in shares of Seres Therapeutics during the fourth quarter worth about $409,000. 59.34% of the stock is currently owned by institutional investors and hedge funds.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.